<DOC>
	<DOCNO>NCT01068353</DOCNO>
	<brief_summary>The primary aim study determine safety tolerability etanercept subject Alzheimer 's Disease . The effect etanercept cognitive , behavioural , functional immunological outcome examine secondary aim .</brief_summary>
	<brief_title>Safety Tolerability Etanercept Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Male female patient age &gt; 54 year Have minimum 7 year education Be able hear , read , write perform study neuropsychological test English Have adequate visual auditory acuity allow neuropsychological testing base research clinician 's judgement Fulfil Diagnostic &amp; Statistical Manual ( DSMIVTR ) criteria diagnosis dementia Alzheimer type Have diagnosis probable Alzheimer 's Disease ( National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criterion ) Mini Mental State Examination ( MMSE ) score &lt; 27 &gt; 10 point . To currently take take cholinesterase inhibitor minimum period 3 month prior day inclusion study take cholinesterase inhibitor minimum period 3 month prior day inclusion study Have informant spends least 24 hour per week patient may close friend neighbour , necessarily close relative , spouse , son daughter . He/she throughout study present visit . If becomes necessary , change informant make must clearly document . Inability refusal provide inform consent patient caregiver Absence informant Unlikely cooperate study , able attend schedule examination visit , able follow study instruction Participation another study administration investigational drug previous 3 month already enrol another study Parkinson 's Disease , Dementia Lewy Bodies clinically significant Parkinsonian symptom Vascular disorder ( modify Hachinski Ischaemic Scale score &gt; 4 ) Recent Transient Ischaemic Attack ( TIA ) within last 3 month Signs major cerebrovascular disease MRI CT scan , perform prior entry study ( i.e . presence infarction great 25 % white matter , 1 lacune within basal ganglion , 2 lacunes white matter ) Any previous ongoing chronic recurrent disease central nervous system , include demyelinate disease psychiatric disease , may impact cognitive performance , leave research clinician 's judgement Any follow laboratory abnormality screen visit : ) Clinically significant Vitamin B12 level less low limit normal ii ) Clinically significant folate level less low limit normal iii ) Clinically significant thyroidstimulating hormone ( TSH ) level great upper limit normal clinically significant free thyroxine ( FT4 ) level low low limit normal Patients previous present history severe unstable medical condition ( e.g . hypertension , diabetes leave research clinician 's judgement ) Current alcohol &gt; 35 unit per week men , &gt; 28 unit per week woman , drug abuse discretion research clinician Surgical intervention plan study period . Treatment immunosuppressive drug and/or oral prednisone great 10mg/day within past 90 day Treatment Memantine within past 3 month Vaccination immunization live vaccine ( eg : polio , rubella , yellow fever ) pneumococcal vaccine within past 30 day . Pregnancy breast feed . Severe hepatic , renal cardiac disease . Previous use Tumour Necrosis Factoralpha ( TNFα ) agent . Known skin photosensitivity . Infection past 4 week active infection . Heart failure : New York Heart Association ( NYHA ) Grade 34 . History blood disorder current WCC ≤ 3.5 x 109/l ; platelet count ≤ 100x109/l ; Hb ≤ 10g/dl . Active latent tuberculosis Rheumatoid arthritis ; psoriasis ; psoriatic arthritis ankylose spondylitis Septic arthritis past 12 month Sepsis prosthesis past 12 month Chronic leg ulcer Indwelling urinary catheter Pulmonary fibrosis History neoplasm / malignancy past 5 year Premalignant condition include Barrett 's oesophagus ; cervical dysplasia ; large bowel polyp Any relevant acute chronic abnormality detect physical neurological examination . Electrocardiogram ( ECG ) laboratory test likely interfere study evaluation research clinician 's judgement Previous exposure amyloid vaccine , monoclonal antibody intravenous immunoglobulin meant treat Alzheimer 's disease</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>TNF-alpha</keyword>
	<keyword>Etanercept</keyword>
</DOC>